Medco Research's Adenoscan approved May 18; Fujisawa will market product.
This article was originally published in The Gray Sheet
MEDCO RESEARCH ADENOSCAN APPROVED MAY 18 by FDA as an injectable coronary vasodilator to be used as "an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately" to undergo stress testing for diagnosis of coronary artery disease. The adenosine product is composed of the endogenous naturally occurring nucleoside 6-amino-9-beta-D-ribofuranosyl-9-H-purine. FDA deemed the product "approvable" April 18.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.